Drug Profile
Exenatide controlled-release - Avadel Pharmaceuticals
Alternative Names: Exenatide extended-release - Avadel; FT 228; GLP-1 XLLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Flamel Technologies
- Developer Avadel Pharmaceuticals
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetes mellitus
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in France (SC, Controlled release)
- 28 Mar 2017 Avadel's Exenatide controlled-release is available for licensing as of 28 Mar 2017. http://www.avadel.com
- 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals